Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Drug Discovery & Development | Whitepapers & Reports

Biologics Solutions: Plasmid DNA - Charles River

29 September 2022
Open document in a new tab

Related Resources

FDA Grant Rare Pediatric Disease Designation to Omeros’s Antibody for C3 Glomerulopathy

Rare pediatric disease designation allows the company to access priority review from the FDA for a new drug application or biologics licence application.
Read More

Regeneron’s Bispecific Gets EU Approval After FDA Rejection

The approval means that the bispecific antibody odronextamab can be used to treat adult patients with relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the EU.
Read More